The impact of socioeconomic factors on quality of life and functional impairment in patients treated for oropharyngeal carcinoma

Jovica Milovanović; Dragoslava Andrejić; Ana Jotić; Vojko Djukić; Oliver Tošković; Katarina Savić-Vujović; Bojan Pavlović; Goran Stojković; Bojan Banko; Andjela Milovanović; Vera Artiko

doi:10.2298/VSP170210134M

Jovica Milovanović Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
Dragoslava Andrejić Primary Heathcare Center “Dr Simo Milošević”, Belgrade, Serbia
Ana Jotić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
Vojko Djukić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
Oliver Tošković University of Belgrade, Faculty of Philosophy, Laboratory for Experimental Psychology, Belgrade, Serbia
Katarina Savić-Vujović University of Belgrade, Faculty of Medicine, Department of Pharmacology, Belgrade, Serbia
Bojan Pavlović Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
Goran Stojković Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
Bojan Banko Clinical Center of Serbia, Center for Radiology and Magnetic Resonance Imaging, Belgrade, Serbia
Andjela Milovanović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Vera Artiko Clinical Center of Serbia, Institute for Nuclear Medicine, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP170210134M

Keywords: papillomaviridae;, socioeconomic factors;, pharyngeal neoplasms;, quality of life;, treatment outcome.

Abstract

Backround/Aim. Considering the distinct increase in the incidence of oropharyngeal cancer over oral cavity cancers and changing epidemiology with human papilloma virus (HPV) infection emerging as an important risk factor, there is a need to establish better treatment choices in specific groups of patients with oropharyngeal cancer. The aim of this study was to assess the quality of life (QOL) and functional performance and the impact of different demographical data, stage of disease, and treatment type on these parameters in patients with oropharyngeal cancer with successfully achieved locoregional control a year after the treatment. Methods. Study included 87 patients who underwent QOL and functional impairment assessment 12 to 14 months after finished oncological treatment with the following questionnaires: the European Organization for Research and Treatment of Cancer Quality-of Life-Questionnaire-C30 (EORTC QLQ-C30), European Organization for Research and Treatment of Cancer Quality of- Life Questionnaire-Head and Neck 35 (EORTC QLQ-H&N35) and The Karnofsky Performance Scale (KPS). Results. Specific groups of patients had significantly different post-treatment QOL scores. The factors associated with the worse QOL scores were female gender, not being in a partnership, level of education and HPV status. Conclusion. Clinicians should consider socioeconomic factors and HPV status in planning the recovery after treatment of patients with oropharyngeal carcinoma. Gender, education level and employment are the variables that form a certain risk profiles associated with the lower QOL.

References

Lambert R, Sauvaget C, de Camargo Cancela M, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and orophar-ynx. Eur J Gastroenterol Hepatol 2011; 23(8): 633–41.

GLOBOCAN. 2012. Available from: http://globocan.iarc.fr/old/summary_table_site_prev.asp?selec-tion=13010&selection=21030&title=Lip%2C+oral+cavity%2C+Other+pharynx&sex=0&africa=1&america=2&asia=3&europe=4&oceania=5&build=6&window=1&so

Warnakulasuriya S. Global epidemiology of oral and oropha-ryngeal cancer. Oral Oncol 2009; 45(4–5): 309–16.

Chandu A, Smith AC, Rogers SN. Health-related quality of life in oral cancer: A review. J Oral Maxillofac Surg 2006; 64(3): 495–502.

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29(32): 4294–301.

Weatherspoon DJ, Chattopadhyay A, Boroumand S, Garcia I. Oral cavity and oropharyngeal cancer incidence trends and dispari-ties in the United States: 2000-2010. Cancer Epidemiol 2015; 39(4): 497–504.

Cleveland JL, Junger ML, Saraiya M, Markowitz LE, Dunne EF, Epstein JB. The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: Implications for dentistry. J Am Dent Assoc 2011; 142(8): 915–24.

Iyer GN, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, et al. Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Be-tween Surgically Treated HPV-Positive and Negative Oropha-ryngeal Cancer. Ann Surg Oncol 2015; 22(13): 4411–21.

Morton RP. Studies in the quality of life of head and neck can-cer patients: Results of a two-year longitudinal study and a comparative cross-sectional cross-cultural survey. Laryngo-scope 2003; 113(7): 1091–103.

Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the de-tection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116(9): 2166–73.

Cai C, Chernock RD, Pittman ME, El-Mofty SK, Thorstad WL, Lewis JS. Keratinizing-type squamous cell carcinoma of the oropharynx: P16 overexpression is associated with positive high-risk HPV status and improved survival. Am J Surg Pathol 2014; 38(6): 809–15.

Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biörklund A, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope 2001; 111(8): 1440–52.

Karnofsky DA, Burchenal JH. The clinical evaluation of chemo-therapeutic agents in cancer. In: MacLeod CM, editor. Evalua-tion of chemotherapeutic agents. New York: Columbia Uni-versity Press; 1949. p. 196–7.

Röösli C, Tschudi DC, Studer G, Braun J, Stoeckli SJ. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope 2009; 119(3): 534–40.

Yasumatsu R, Nakashima T, Komune S. Squamous cell carcino-ma of the oropharynx: single-institution outcome analysis of patients treated with concurrent chemoradiotherapy. J Laryn-gol Otol 2015; 129 Suppl 2: S77–82.

Broglie MA, Soltermann A, Haile SR, Röösli C, Huber GF, Schmid S, et al. Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryn-goscope 2013; 123(1): 164–70.

Binenbaum Y, Amit M, Billan S, Cohen JT, Gil Z. Minimal clinically important differences in quality of life scores of oral cavity and oropharynx cancer pa-tients. Ann Surg Oncol 2014; 21(8): 2773–81.

Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: The clini-cian's perspective. Health Qual Life Outcomes 2006; 4: 62.

Infante-Cossio P, Torres-Carranza E, Cayuela A, Hens-Aumente E, Pastor-Gaitan P, Gutierrez-Perez JL. Impact of treatment on quality of life for oral and oropharyngeal carcinoma. Int J Oral Maxillofac Surg 2009; 38(10): 1052–8.

Bozec A, Peyrade F, Milano G. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: Recent developments and perspectives. Anticancer Agents Med Chem 2013; 13(3): 389–402.

Al-Mamgani A, Rooij P, Tans L, Verduijn GM, Sewnaik A, Baatenburg JR. A prospective evaluation of patient-reported quality-of-life after (chemo) radiation for oropharyngeal can-cer: Which patients are at risk of significant quality-of-life de-terioration. Radiother Oncol 2013; 106(3): 359–63.

Pierre CS, Dassonville O, Chamorey E, Poissonnet G, Ettaiche M, Santini J, et al. Long-term quality of life and its predictive fac-tors after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Eur Arch Oto-rhinolaryngol 2014; 271(4): 801–7.

Vartanian JG, Carvalho AL, Toyota J, Kowalski IGS, Kowalski LP. Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer. Arch Otolaryn-gol Head Neck Surg 2006; 132(1): 32–5.

Demiral AN, Sen M, Demiral Y, Kinay M. The effect of socioeconomic factors on quality of life after treatment in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70(1): 23–7.

Thomas AA, Timmons A, Molcho M, Pearce A, Gallagher P, Butow P, et al. Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncol 2014; 50(7): 676–82.

Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, et al. Clinical predictors of quality of life in pa-tients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004; 130(4): 401–8.

Allal AS, Nicoucar K, Mach N, Dulguerov P. Quality of life in pa-tients with oropharynx carcinomas: Assessment after acceler-ated radiotherapy with or without chemotherapy versus radi-cal surgery and postoperative radiotherapy. Head Neck 2003; 25(10): 833–9; discussion 839-40.

Sharma A, Méndez E, Yueh B, Lohavanichbutr P, Houck J, Doody DR, et al. Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories. Otolaryngol Head Neck Surg 2012; 146(5): 739–45.

Maxwell JH, Mehta V, Wang H, Cunningham D, Duvvuri U, Kim S, et al. Quality of life in head and neck cancer patients: Im-pact of HPV and primary treatment modality. Laryngoscope 2014; 124(7): 1592–7.

Oates J, Davies S, Roydhouse JK, Fethney J, White K. The effect of cancer stage and treatment modality on quality of life in oro-pharyngeal cancer. Laryngoscope 2014; 124(1): 151–8.

Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottels-berghe C, Curran D, et al. A 12country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck can-cer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36(14): 1796–807.

Kim TW, Youm H, Byun H, Son Y, Baek C. Treatment Out-comes and Quality of Life in Oropharyngeal Cancer after Sur-gery-based versus Radiation-based Treatment. Clin Exp Oto-rhinolaryngol 2010; 3(3): 153–60.

Boscolo-Rizzo P, Stellin M, Fuson R, Marchiori C, Gava A, Da Mosto MC. Long-term quality of life after treatment for locally advanced oropharyngeal carcinoma: Surgery and postoperative radiotherapy versus concurrent chemoradiation. Oral Oncol 2009; 45(11): 953–7.

Mowry SE, Ho A, Lotempio MM, Sadeghi A, Blackwell KE, Wang MB. Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope 2006; 116(9): 1589–93.

Chen AM, Daly ME, Luu Q, Donald PJ, Farwell GD. Compari-son of functional outcomes and quality of life between tran-soral surgery and definitive chemoradiotherapy for oropharyn-geal cancer. Head Neck 2015; 37(3): 381–5.

Günzel T, Schimmer M. Quality of life after primary radiation/radio-chemotherapy vs. operation therapy in an oropharyngeal cancer. Laryngorhi-nootologie 2012; 91(7): 451–6; quiz 457–9. (German)

Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM, Li JG. In-tensity modulated radiotherapy for oropharyngeal squamous cell carcinoma. Laryngoscope 2010; 120(2): 218–22.